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The purpose of this study was to mask the bitter taste imparted by dihydroartemisinin (DHA) by the 
use of different coating materials. Trial-1 and trial-2 were conducted to prepare the DHA granules. The 
granules produced from trial-1 were irregular in shape and smaller in size while the trial-2 granules 
were more regular and larger in size. The granules obtained from both trials were then coated with 
two different coating methods, namely A and B, depending upon coating material. The trial-2 granules 
showed better flow properties than trial-1 granules. In vitro dissolution studies in phosphate buffer at 
pH 6.8 revealed that granules of trial-2B released only 34% ± 3 DHA in two minutes compared with 
trial-1A (57% ± 2), trial-1B (48% ± 2) and trial-2A (53% ± 7). The pleasant taste perception (PTP) test 
also confirmed the taste masking efficacy of trial-2B (P < 0.05). Scanning electron microscopy (SEM) 
revealed the more regular and smooth surface of trial-2B granules. In addition, the differential thermal 
and thermogravimetric analysis (TG-DTA) confirmed no interaction between the materials and pure 
DHA. DHA has shown its characteristic peaks in the x-ray diffraction (XRD) patterns which were also 
prominent in all the granules. In conclusion, the granules obtained from trial-2B displayed considerable 
decrease in the bitter taste of DHA thereby fulfilling the purpose of this study.
Uniterms: Medicines/coating. Granules/coating. Dihydroartemisinin (DHA)/taste masking. 
Thermogravimetric analysis/medicines analysis. X-ray diffraction/medicines analysis.
O objetivo deste estudo foi o de mascarar o gosto amargo característico da diidroartemisinina (DHA) 
pelo uso de diferentes materiais de revestimento. Experimento-1 e experimento-2 foram realizados 
para preparar grânulos de DHA. Os grânulos produzidos pelo experimento-1 mostraram-se irregulares 
e menores se comparados aos obtidos pelo experimento-2, que foram mais regulares e maiores. Os 
grânulos obtidos em ambos os experimentos foram, então, revestidos por dois métodos distintos de 
revestimento, designados como A e B, dependendo do material de revestimento empregado. Os grânulos 
do experimento-2 mostraram melhor propriedade de fluxo que os obtidos no experimento-1. Estudos 
de dissolução in vitro em tampão fosfato pH 6,8 revelaram que grânulos do experimento-2B liberaram 
apenas 34% ± 3 da DHA em dois minutos se comparado com experimento-1A (57% ± 2), experimento-1B 
(48% ± 2) e experimento-2A (53% ± 7). A Análise Sensorial quanto ao sabor (Pleasant Taste Perception - 
PTP) também confirmou a eficácia do experimento-2B (P <0,05) em mascarar o gosto amargo da DHA. 
Microscopia Eletrônica de Varredura (SEM) revelou a superfície mais regular e lisa dos grânulos obtidos 
pelo experimento-2B. Além disso, Análise Termogravimétrica e Análise Térmica Diferencial (TG-DTA) 
confirmaram que não há nenhuma interação entre os materiais e a DHA pura. DHA mostrou seus picos 
característicos na Difração de Raios X (XRD) em padrões que também foram proeminentes em todas 
as amostras. Em conclusão, os grânulos obtidos pelo experimento-2B exibiram diminuição considerável 
no gosto amargo da DHA, o que era o propósito deste estudo.
Unitermos: Medicamentos/revestimento. Granulados/revestimento. Diidroartemisinina. Granulados. 
Análise termogravimétrica/análise de medicamentos. Difração de raio X/análise de medicamentos.
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INTRODUCTION
Bitter, astringent, metallic or unpleasant tastes are 
highly unacceptable if using the oral route of delivery, es-
pecially in the case of pediatric drugs (Roy, 1994; Szejtli, 
Szente, 2005). The majority of the orally administered 
drugs including alkaloids such as quinine, and antibiotics 
such as sparfloxacin or clarithromycin, are bitter in taste 
(Shirai et al., 1993, 1994; Katsuragi et al., 1995, 1997; Ya-
jima et al., 1999). However, for patients, such drugs are not 
necessarily easy to swallow, resulting in non-compliance 
and a subsequent decrease in efficacy. To overcome this 
problem various techniques have been developed to mask 
the unpleasant and bitter taste of drugs including capsules, 
coated tablets, microencapsulation, complexation and 
chemical modification (Cuña et al., 1997; Barra et al., 
1999). But in most cases, solid preparations like tablets 
and capsules are not recommended for pediatric patients, 
instead liquid preparations are used. It is known that only 
dissolved substances elicit taste sensation and substances 
which are completely insoluble in water are tasteless. In 
many cases, however, the drugs are so intensely bitter, 
that they are barely tolerable even at ppm levels (Szejtli, 
Szente, 2005).
The most effective method of achieving maximum 
taste masking is to coat the drug particles, thereby creating 
a physical barrier around the drug. This may be achieved 
using microencapsulation techniques such as spray-drying 
(Yajima et al., 1999; Wilson et al., 1994), spray-congealing 
(Shimano et al., 1995; Robson et al., 1999), coacervation 
(Chukuwu et al. 1991; Al-Omranm et al., 2002) or the sol-
vent evaporation method (Hashimoto et al., 2002).
Dihydroartemisinin (DHA), a more water-soluble 
metabolite of artemisinin derivatives, is a safe and highly 
effective antimalarial analog of artemisinin (Chen et al., 
2004). It is isolated from the traditional Chinese herb Arte-
misia annua, and recommended as a first-line anti-malarial 
drug with low toxicity (Dhingra et al., 2000). This drug 
has a very bitter taste and therefore serves as a model drug 
to evaluate taste-masking efficiency for several kinds of 
oral formulations.
In the present investigation, our goal was to pre-
pare DHA granules using the wet granulation technique 
(Ameye et al., 2002) and to apply enteric coating by using 
different coating materials to mask the bitter taste of DHA. 
The influence of these coatings on the surface morphology 
of granules were then examined using scanning electron 
microscopy (SEM) as well as the influence on their dis-
solution behavior at pH 6.8 of the oral cavity. In addition, 
the palatability of the granules was evaluated in a pleasant 
taste perception (PTP) test. Finally, differential thermal 
analysis (DTA), thermogravimetric analysis (TGA), and 
x-ray diffraction (XRD), was used to investigate possible 
interactions between the components of the formulation.
EXPERIMENTAL
Materials
Dihydroartemisinin (DHA) was a gift sample from 
AMSON Vaccines & Pharma (Pvt.) Ltd. Islamabad, Pakis-
tan. Methocel® E5 was obtained from Dow Chemical 
Co., Midland. Opadry® was purchased from Colorcon, 
West Point, PA. Carbopol 934P was obtained from B.F 
Goodrich, Cleveland, OH, USA. Polyvinylpyrrolidone 
(PVP-K30) and isopropyl alcohol (IPA) were obtained 
from Fluka (Buchs, Switzerland). Acetonitrile was 99% 
HPLC grade (Merck, Germany). All the chemicals and 
reagents were of analytical grade.
Chromatographic conditions and analysis
The DHA analysis was performed on a HPLC Gra-
dient SPD 10 A (Schimadzu) with UV detector at 209 nm. 
The HPLC was equipped with a 20 µL loop Rheodyne 
injector. A symmetry C-18 column (Waters corporation, 
5 µm, 4.6 x 150 mm i.d.) was used as the stationary phase. 
The mobile phase was prepared by mixing HPLC grade 
acetonitrile and water (milli-Q) in a 35:65 v/v ratio and 
vacuum filtering it through a 0.45 µm nylon filter. Filtered 
solvents were degassed before use. The flow rate was set 
at 1.2 mL/min (Ansari et al., 2009).
Solubility studies
The test samples were prepared in water with an ex-
cess amount of pure DHA and placed on an orbital shaker 
at 100 rpm for five days in a temperature controlled room 
at 37 oC. Samples were centrifuged and withdrawn with a 
syringe equipped with a 0.40 μm syringe filter. All samples 
were diluted and immediately analyzed with HPLC for 
drug content. Samples were prepared in duplicate (Ansari 
et al., 2009).
Preparation of granules
The wet granules of DHA were prepared using two 
trials in a laboratory-scale low-shear mixer. The formu-
lation of each trial is given in Table I. The batch size was 
500 g for each trial (trial-1: granulation with starch, PVP-
K30, and IPA in 100 mL of distilled water, and trial-2: 
granulation with Carbopol 934P, sodium metabisulphite, 
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and methyl paraben sodium in 150 mL of distilled water). 
The impeller speed was set at 100 rpm for 10 min in all 
the trials to mix the powders, then, during addition of 
the granulation liquid, the impeller speed was raised to 
400 rpm for 10 minutes to wet the whole powder mixture.
Finally, the granules were dried at a reduced pressure 
at 60 °C with an impeller speed of 100 rpm for 10 s every 
100 s, while tilting the bowl to move the granules increa-
sing the surface exposed to the evaporation process. The 
drying time, as a function of the amount of water used, was 
25 minutes for trial-1, and 30 min for trial-2. Therefore, the 
total granulation time was 45 min for trial-1, and 50 min 
for trial-2. The granules were spread out in thin layers in 
a tray allowing them to cool at room temperature, then 
collected and sieved as described in the following section.
Coating of granules
Coating was undertaken to mask the bitter taste and 
to improve the aesthetic appeal of the formulated granules 
of DHA. For this purpose, two coating methods namely 
A and B were used to coat the granules of each trial-1 
and 2 in conventional coating pans. In coating method A, 
Methocil™ E5 (60 g) was mixed in 250 g of IPA with fast 
stirring. Titanium dioxide (6 g) and talcum (10 g) were 
then dissolved in 50 mL of methylene chloride. Both the 
solutions were then mixed together for 10 minutes for uni-
formity and then filtered. In coating method B, Opadry® 
enteric (30 g) was mixed in methylene chloride (50 mL) 
and IPA (300 g) with fast stirring for 40 minutes. A small 
quantity of methylene chloride was added and mixed for 
another 10 minutes for uniformity and then filtered. The 
trials were designated as trial-1A & trial-1B, and trial-
2A & trial-2B based on the method of coating applied to 
each formulation respectively. A laboratory scale coating 
pan (SH-506, Taiwan) was used to coat the granules. The 
operating speed of pan was 20 rpm with high atomization 
and slow air speed. The distance of the coating gun was 
25 inches from the granules bed for efficient coating. The 
granules were dried after coating by blowing hot air.
Characterization of Granules
Granule size distribution
The granule size distribution was evaluated by 
sieve analysis, using a vibrating shaker (Octagon Digital, 
Endecotts, London, UK) at a medium vibration level for 
15 min and three standard sieves (Scientific Instruments 
s.r.l., Milan, Italy) in the range 250–2000 um. The fractions 
were then collected and stored in desiccators at 30±2 °C. 
The granulation tests were performed at least in duplicate 
and the mean of each particle size ± standard deviation 
(S.D.) was then calculated.
Rheological study of formulated granules
The rheological properties of formulated granules 
were determined by Carr’s index (Leon, et al., 1986): 
Where ρp is the poured density described by mass of 
sample granules divided by the undistributed volume in 
a 10 mL cylinder after filling, and ρt is the tapped density 
described by mass of sample granules per unit volume 
after tapping a bed of granules, after no change of volume 
was observed.
Drug content estimation
The analysis of the DHA content in each fraction was 
carried out by dissolving 50 mg of granules in 100 mL of 
phosphate buffer at pH 6.8 (within the pH range of saliva); 
the amount of the drug was then determined by HPLC 
Gradient SPD 10 A (Schimadzu) at 209 nm. Each fraction 
was analyzed in triplicate.
In vitro dissolution studies
In vitro dissolution tests were performed using the 
USP 24 paddle method (Pharmatest, Steinhein, Germany) 
rotating at 60 rpm. A volume of 900 mL of pH 6.8 phos-
phate buffer was used at a temperature of 37 ± 1 °C to 
evaluate the taste-masking efficiency of the granules. Each 
sample contained 35 mg of DHA. The samples were taken 
at a pre-determined time and analyzed by HPLC Gradiant 
SPD 10 A (Schimadzu). The amount of drug dissolved was 
analyzed at 209 nm. The dissolution tests were performed 
TABLE I - Formulation of DHA granules
Trial 1 Trial 2
Ingredients Quantity Ingredients Quantity
DHA 350 g DHA 350 g
Starch 30 g Carbapol 25g
PVP-K30 40 g Sodium 
Metabisulphite
50 g
IPA 80 ml Methyl 
Paraben 
Sodium
75 g
DI water QS DI water QS
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in triplicate and the three absorption values were averaged 
and their S.D. was then calculated.
Pleasant taste perception (PTP) test
The PTP test was performed by six volunteers at 
the Gustatory Evaluation Laboratory of the Institute of 
Biotechnology, Bahauddin Zakariya University Multan 
(Pakistan). The involvement of human volunteers in this 
study was ethically approved by the Gustatory Evaluation 
Laboratory of the Institute of Biotechnology, Bahauddin 
Zakariya University. To find a suitable concentration for 
the evaluation of the bitterness taste intensity during the 
comparative test, the perception and bitterness recogni-
tion threshold of pure DHA was evaluated as described 
previously (Beatrice et al., 2004).
To determine the threshold of bitterness, seven stan-
dard solutions of pure DHA in distilled water at different 
concentrations were prepared as follows: 
I. 0.00% (w/v); II. 0.01% (w/v); III. 0.025% (w/v); 
IV. 0.05% (w/v); V. 0.1% (w/v); VI. 0.2% (w/v) and VII. 
0.4% (w/v). 
The volunteers were then asked to taste 5ml of 
solution IV by keeping it in their mouth for 5 Seconds. 
Then, they were required to give one of these following 
perceptions:
1. “I feel a bitter taste”.
2. “I do not feel any difference between solutions IV and I”,
3. “I feel something but I can not identify the taste”,
The volunteers whose answer perception was 2 or 3 
were then asked to taste solution V (having a higher drug 
concentration than IV), while volunteers whose answer 
perception was 1 were then asked to taste solution III. 
The results yielded the perception threshold at 0.05% 
(w/v) (range 0.025–0.08%, w/v) and bitterness recognition 
threshold at 0.08% (w/v) (range 0.06–0.2%, w/v). Subse-
quently, in order to have homogeneity in the sensation of 
the bitterness intensity among the volunteers, a trained 
panel evaluation was performed testing some solutions at 
different concentrations of DHA and the volunteers were 
told the bitterness scores (from 0 to 100) of these solutions.
The evaluation of the granules taste was then carried 
out by dispersing 250 mg of each sample in 100 mL of water 
to obtain a 0.21% (w/v) DHA granules suspension, which is 
higher than the bitterness recognition threshold. The granule 
particle size was the same as that used for the dissolution 
tests. The PTP test was performed on the granule suspension 
instead of the solid sample to evaluate if the in vitro drug 
release of the four samples could reflect upon the bitterness 
sensation after the same time (2 min) and also to reduce the 
wide variability of drug concentration in the mouth, because 
of the different salivation conditions between volunteers, 
occurring when a solid sample is used.
The volunteers were then asked to taste 5 mL of each 
sample as previously described and to give a bitterness 
score (based on a 0.21% (w/v) granule suspension bitter-
ness score of 100). Significant differences among granules 
were analyzed using the unpaired student’s t-test and a 
value of P<0.05 was considered significantly different.
Scanning electron microscopy (SEM)
The surface morphology of the developed formula-
tions was examined using a scanning electron microscope 
(Hitachi S-6000).
Differential thermal & thermogravimetric 
Analysis (TG-DTA)
The thermal stability of DHA granules was studied. 
For this, simultaneous TG-DTA experiments were per-
formed using a Linesis STA PT 1600 instrument under an 
air flow of 100 mL/min at heating rate of 5 °C/min with 
an initial sample mass of 5 mg. Alumina crucibles were 
used for analysis.
X-ray diffraction (XRD)
X-ray powder diffraction (XRD) for DHA and granu-
les was performed using a Bruker D8 Discover (Germany) 
apparatus. Measurement conditions included target (CuKα), 
voltage (35 KV), and current (35 mA). A system of diver-
ging, receiving, and anti-scattering slits of 1o, 1o, 0.15o, 
respectively, were used. Eva software was used for the data 
processing (Evaluation Package Bruker, Germany). Patterns 
were obtained using a scan speed of 4 degree/minute with 
2θ between 6o, and 35o (Ansari et al., 2009).
RESULTS AND DISCUSSION
DHA granules were prepared by the conventional 
wet granulation method and characterized to confirm the 
suitability of granulation and coating method for reducing 
the unpleasant taste of the drug. DHA being a lipophilic drug 
showed low solubility in water as expected i.e. 0.12±0.01 
mg/mL. The result obtained is very similar to a previous-
ly reported result (Ansari et al., 2009). The Carr’s index 
for trial-1 granules was 17.4 and 12.6 for trial-2 granules 
which indicates the better flowability of trial-2 granules as 
compared to trial-1 granules. Both the trials were designed 
to produce granules of better quality and to test the coating 
technique which favors more regular shaped granules. The 
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TABLE II - Content of DHA granules as a function of particle size
Size of Particles (µm) Theoretical amount of DHA 
per 50 mg of Granules (mg)
Actual amount of DHA calculated in mg* (% drug Loading)
Trial-1 Trial-2
250<x<500 35 29.97 ± 0.97 (84.48) 30.44 ± 0.78 (86.97)
500<x<1000 35 29.51 ± 1.01 (84.31) 30.93 ± 0.45 (88.37)
1000<x<2000 35 30.13 ± 1.12 (86.08) 30.99 ± 0.91 (88.54)
*Values are given as mean ± S.D
FIGURE 1 - Granule size distribution.
FIGURE 2 - SEM pictures of trial-1A (A) 30x and (B) 100x; 
trial-1B (C) 40x and (D) 80x; trial-2A (E) 80x and (F) 120x; 
trial-2B (G) 50x and (H) 80x.
granules produced from trial-1 were of smaller size mainly 
due to the addition of PVP (Beatrice et al., 2004). The granu-
les produced from trial-2 were bigger in size than granules 
of trial-1. For trial-1, the cumulative frequency percent was 
42 for granules having a size of 250 µm, 35 for 500 µm and 
22 were greater than 1000 µm, respectively (Figure 1). For 
trial-2, the cumulative frequency percent was only 19 for the 
250 µm size range, 43 for 500 µm and 35 were greater than 
1500 µm. Overall trial-2 yielded larger granules compared 
with trial-1. The yield of granules from granulation trial-1 
and trial-2 was 94% (w/w) and 95% (w/w) respectively, 
which represents a very small loss of material during the 
granulation process. 
Secondly, coating method A & B were considered 
using SEM. Trial-1A produced granules which were not 
sufficiently regular in shape to be considered ideal. This was 
also the case with the granules of trial-1B and trial-2A. Ho-
wever, coating method B when employed in trial-2 produ-
ced granules which were more regular in shape than any of 
the other trials (Figure 2). These granules were considered 
ideal for masking the bitter taste of DHA. The content of 
DHA in each fraction of trial-1 and trial-2 was also measu-
red as described in the Methods section of this paper. Table 
2 represents the actual amount of DHA in the formulated 
granules which was uniformly distributed in the range of 84 
-88 % (w/w) of the theoretical mass for both trials.
The results of the pleasant taste perception test, per-
formed by six volunteers, indicated that the taste-masking 
strategy is related not only to the granulation method but 
also the choice of coating material and formulation me-
thod. The trial-1A, trial-2A, trial-1B, and trial-2B granule 
solutions had bitter taste intensity scores of 87.5 (S.D. = 
4.63; P > 0.05), 80.5 (S.D. = 4.8; P > 0.05), 74.16 (S.D. 
= 3.14; P > 0.05), and 47.33 (S.D. = 5.81; P < 0.05), res-
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pectively. These data confirm that the trial-2B granules 
successfully masked the bitter taste of DHA compared to 
the other formulations. The in vitro dissolution profiles of 
the granules were performed in phosphate buffer at 6.8 pH, 
which lies in range of saliva pH (6.2-7.4), and compared 
to those of pure DHA (Figure 3). The results comply with 
the findings of the PTP test. The dissolution of drug in 2 
minutes is of particular interest as it suggests the dissolved 
amount is below the threshold of taste as observed in the 
PTP test. The dissolution profile of pure DHA was relati-
vely high (64% ± 4 at 2 min) followed by trial-1A (57% ± 
2), trial-2A (53% ± 7), and trial-1B (48% ± 2). However 
the trial-2B formulation showed the lowest in vitro drug 
release and only 34% ± 3 was dissolved after 2 minutes. 
From the result, it is clear that trial-2B granules could 
represent the suitable pharmaceutical form to mask the 
bitter taste of DHA without modifying its release which 
was found to be almost 98% in all trial samples.
To study the effect of formulation on the solid state 
of DHA, differential thermal analysis (DTA), thermo-
gravimetric analysis (TGA) and x-ray diffraction (XRD) 
studies were conducted. Thermal and gravimetric analyses 
were performed at a typical storage temperature of 30 °C 
to reflect the climate where this research was conducted. 
The DTA curves (Figure 4) revealed the thermal stability 
of granules at the studied temperature confirming that 
from 30-125 °C, the granules are completely stable. The 
TG curves (Figure 5) for all granule trials were similar and 
with minimal decrease in weight from 30-125 °C. These 
results suggest that the granules have shown significant 
thermal stability in relation to the pure DHA. 
XRD patterns display the characteristic peaks of 
DHA as described in earlier studies (Ansari et al., 2009). 
This confirms the presence of the crystalline form of DHA 
and no phase transformations were seen in any of the for-
mulations (Figure 6).
FIGURE 3 - In vitro dissolution profile of DHA granules.
FIGURE 4 - DTA comparison of pure DHA and DHA granules.
FIGURE 5 - TGA comparison of pure DHA and DHA granules.
FIGURE 6 - XRD comparison of pure DHA and DHA granules.
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CONCLUSION
In conclusion, it was possible to reduce the bitter-
ness of DHA using coating method B (coating material: 
Opadry enteric, methylene chloride and IPA) with granules 
of trial-2, confirmed by taste perception tests and in vitro 
dissolution testing. Trial-2 granules showed excellent 
flowability. The SEM showed a more regular coating on 
the surface of trial-2B granules which means an efficient 
coating on the surface of granules can inhibit the early es-
cape of drug from granules resulting in less impart of bitter 
taste. The granules showed acceptable thermal stability 
and no phase transformations were revealed, therefore, 
no interaction was evident between the excipients and 
DHA itself. The present study has described a novel taste 
masking strategy which can possibly be used for other 
drugs in future studies.
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